GW296115 is a multi-target inhibitor with the following IC 50 values against its targets: 8.4 nM for BRSK2 , 21 nM for BRSK1 , 1.8 μM for PDGFRβ , 5.5 nM for STK17B/DRAK2 , 28 nM for DRAK1 , 20 nM for PHKG1 , and 89 nM for DCAMKL3 . GW296115 downregulates the phosphorylation of S317 site on ULK1 and S351 site on P62 , which are AMPK substrates driven by BRSK2 . GW296115 does not alter the phosphorylation level of AMPK at T172, reduces nutrient deprivation-mediated Autophagy and autophagosome formation, and enhances Apoptosis . GW296115 exhibits anticancer activity against triple-negative breast cancer . GW296115 is applicable for breast cancer-related research.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > DAPK | Products > Signaling Pathways > ULK | Products > Signaling Pathways > p62 | Products > Signaling Pathways > Autophagy
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.